CA-FORESCOUT-TECH
6.6.2022 15:02:12 CEST | Business Wire | Press release
Forescout Technologies, Inc. , the global leader in automated cybersecurity, today announced that it has signed a definitive agreement to acquire Cysiv , a cybersecurity innovator that uses its cloud platform to improve detection and response of true threats. With this acquisition, Forescout will leverage Cysiv’s threat detection engine to analyze a wealth of asset and network communications data automatically collected by Forescout’s platform. This comprehensive data across IT, IoT, OT and IoMT devices, as well as other essential data sources, enables better true threat detection and response so customers can operate more securely and efficiently. Upon the close of the acquisition, Cysiv will join Forescout.
“Organizations need to be able to reduce the billions of data points on their networks to a handful of actionable true threats – automatically. Together with Cysiv, Forescout will provide customers with the most powerful platform for automated cybersecurity across their digital terrains,” said Wael Mohamed, CEO of Forescout. “Upon close, the acquisition will help our customers leverage actionable threat intelligence from comprehensive data collected by Forescout and analyzed by Cysiv. We will receive far more than just great technology in this acquisition. The Cysiv team is exceptional, and our two organizations are highly complementary.”
Today, organizations are faced with the immense pressure to secure their networks. CIOs and CISOs have experienced rapid growth in the volume and diversity of managed and unmanaged devices, including IoT devices, that has given rise to increased risks and cybersecurity threats, coinciding with a drop in available cybersecurity resources. With the rapid adoption of cloud, and a cloud-first mindset that’s been accelerated by the work-from-anywhere shift of the past two years, enterprises are particularly concerned with managing threats to these fluid threat environments. This has resulted in organizations not being able to effectively manage the detection, investigation, escalation and response of true threats, particularly as the threat landscape and unmanaged device landscape have become more complex.
Existing solutions for threat detection and response, such as EDR, require the use of agents on managed devices. This means that organizations dependent on an agent-based approach for threat detection and response are not able to look for threats coming from the majority of their connected devices, particularly critical assets like IoT, IoMT and OT.
For over a decade, Forescout’s ability to deeply integrate into the fabric of customers’ networks has enabled it to collect real-time data for all connected assets and users, together with the communications among those assets and users. Customers have been asking Forescout to leverage this comprehensive data to provide greater insight into threats for all types of assets and to enable faster, more automated response and remediation.
“We have always been on a mission to provide better threat detection and faster response,” said Partha Panda, CEO and co-founder of Cysiv. “After successfully partnering together for the last year, we are thrilled to join Forescout as we continue on the next stage of our journey. The combination of Forescout and Cysiv will provide organizations with best-in-class threat detection together with automated incident prioritization and automated response.”
The acquisition is expected to close in July, 2022, subject to the satisfaction of closing conditions and receipt of applicable regulatory approvals and comes on the heels of its acquisition of CyberMDX which further strengthens Forescout’s industry-leading IT, IoT and OT device coverage with IoMT expertise.
About Forescout
Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
© 2022 Forescout Technologies, Inc. All rights reserved. Forescout Technologies, Inc. is a Delaware corporation. A list of our trademarks and patents can be found at https://www.forescout.com/company/legal/intellectual-property-patents-trademarks . Other brands, products, or service names may be trademarks or service marks of their respective owners.
About Cysiv
Cysiv security operations center (SOC)-as-a-service provides enterprises with better detection and faster response of true threats. We do this by uniquely combining our cloud-native next generation SIEM, with a data-centric approach and a team of experts that operate as a seamless extension of your SOC. All of this is delivered as a subscription-based service, with predictable and flexible pricing, that can be operational in weeks. Cysiv’s modern approach to threat detection and response helps reduce risk, ensure compliance, and improve the efficiency, effectiveness and maturity of your security operations. To learn more, visit www.cysiv.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005321/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
